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Summary This is the first prospective study of unnary measures of the two major competing pathways of oestrogen metabolism, 16a-
hydroxyoestrone (16a-OHE1) and 2-hydroxyoestrone (2-OHEl), in relation to incident breast cancer risk. Experimental and case-control
study results suggest that metabolism favouring the more oestrogenic 16a-OHE1 pathway may be linked to higher breast cancer risk. Women
aged 35 and older from Guemsey (n = 5104) were surveyed in 1977-85 and have been continuously monitored for breast cancer and
mortality up to the present (Guemsey 1II, Imperial Cancer Research Fund). Incident cases of breast cancer were matched to three control
subjects for comparison of urinary oestrogen metabolite levels measured by enzyme immunoassay (EIA) in spot urine samples collected at
baseline and stored frozen for up to 19 years. Consistent with case-control study results, post-menopausal (but not premenopausal) women
at baseline who went on to develop breast cancer showed about a 15% lower 2:16ct-OHE1 ratio than matched control subjects. Further,
subjects with metabolite ratios in the highest tertile of 2:16a-OHE1 had about a 30/o lower risk than women with ratios in the lowest two-
thirds, although results were not statisticalty significant (OR = 0.71, 95% Cl = 0.29-1.75). It is of potential importance that, in contrast to most
risk factors for breast cancer, such as late age at first birth, oestrogen metabolism appears to be modifiable via diet and exercise, offering
women the possibility of lowering breast cancer risk through non-pharmacological measures, although this remains to be tested.
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This is the first study to examine oestrogen metabolites wele
before the onset of breast cancer: median follow-up time to diag-
nosis was 9.5 years (quartile 1 = 6 years. quartile 3 = 13 years).
Prospective studies have not included measures of oestrogen
metabolism as they have been complicated and invasive. involving
radiolabelled tracers. The development of a new assay now allows
oestrogen metabolites to be measured on stored unrne specimens
without the use oftracers. Substantial evidence shows oestrogen to
be implicated in breast carcinogenesis. but mechanisms remain
unclear. Experimental and case-control study results have shown
that metabolism of oestrogen that favours the 16a-hydroxy-
oestrone (16a-OHE1) over the 2-hydroxyoestrone (2-OHEI)
pathway may increase risk of breast tumours. To test this hypoth-
esis we have measured 2-OHE1 and l6a-0HE1 in stored urine
from incident breast cancer cases and matched control subjects
among participants in the island ofGuemsey (Guemsey HI) popu-
lation-based prospective study ofbreast cancer risk.
Measures of oestrogen metabolism as markers for
breast cancer risk
Oestradiol is oxidized to vield oestrone. A-hich then is hvdroxvl-
ated (via the cvtochrome P450-dependent steroid hydroxylases) in
penpheral tissue including breast (Telang et al. 1997) by one of
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two irreversible and mutually exclusive pathways to form: (1)
16a-hydroxyoestrone or (2) 2-hydroxyoestrone. These are the
major metabolic pathways for oestrogen with 4-hydroxylation as a
minor pathway. albeit one that produces a carcinogenic product.
The 2- and l6a-hydroxylation appear to compete for the limited
oestrone substrate pool. and a rise in the extent of one hydroxvla-
tion pathway will result in a shift ofsubstrate towards the alternate
and will reduce the absolute amount of the product of the
competing, pathway.
The 16at- and 2-OHEI metabolites are thought to have markedlv
different biological properties. The major metabolites of oestrogen
hydroxylated at the C-16a position (16a-hydroxyoestrone and
oestriol) are oestrogenic (Martucci and Fishman. 1979). with
uterotropic activity comparable with that ofoestradiol. and. having
little affmiity for sex hormone-binding globulin. may be more
readily available to penrpheral tissue (Fishman and Martucci.
1980). Although 16a-OHEl binds to the oestrogen receptor with
only 390 ofthe affmity ofoestradiol. unlike oestradiol. once bound
it fails to down-regulate the receptor. thusincreasing, its potential to
hyperstimulate target tissues. Further. 16a-OHEl appears to be
grenotoxic (Telang et al. 1992). In contrast 2-OHE1 does not appear
to be genotoxic nor to promote cell proliferation or transformation
(Martucci and Fishman. 1979). although there is not universal
agreement on this (Lottering et al. 1992: Lemon et al. 1992).
Formation of 16a-hydroxyoestrone has been found to be elex ated
in women at high n'sk of breast cancer (Osborne et al. 1988). in
women with atypical hyperplasia or proliferative breast disease
(Telang. 1996) and in strains of mice susceptible to breast cancer.
with a strong correlation between the extent of 16a-hydroxylation
and incidence ofmammary tumours in the murine model (Bradlow
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et al. 1985). Recent experimental work (Telang et al. 1997) has
shown DNA synthesis to increase and the 2:16a-OHEI metabolite
ratio to decrease with exposure of breast tissue (terminal duct
lobular units) to a known carcinogen. benzo(a)pyrene: these effects
were then reversed by administration of indole-3-carbinol. a phyto-
chemical found in cruciferous vegetables.
Although one breast cancer case-control study in pre-
menopausal Awomen found no difference in metabolite ratios
betseen breast cancer cases and control subjects (Adlercreutz et
al. 1989). several studies that included post-menopausal women
have reported breast cancer patients to have a 12-60% higher 16a-
hydroxylation than healthy control subjects (Schneider et al. 1982:
Ursin et al. 1997: Kabat et al. 1997: Zheng et al. 1997). The largest
study (with 42 cases and 64 control subjects) (Kabat. 1997) found
a strong, inverse relation of breast cancer risk and 2:16a-OHE1
among post- but not premenopausal subjects.
Whereas studies to date have measured oestrooen metabolites in
women diagnosed with breast cancer. the present study was
designed to determine whether the ratio of2: 16a-OEH1 in asingle
spot unne sample has the potential to serve as a marker for subse-




During 1977-85. 5104 women aged 35 and older livina in
Guemsey participated in a population-based sun-ey on factors
thought to be associated with breast cancer risk. Of the age-
eligible women on the island. 31% volunteered to be surveyed.
The survey. conducted by the Imperial Cancer Research Fund
(ICRF). included questionnaires. mammography and collection of
urne samples. both early morning and 24 h. The ICRF provided
breast cancer incidence and mortality sur eillance.
For the current study. subjects who developed a primary clini-
cally diagnosed breast cancer during the follow-up period (but at
least 6 months after baseline) were considered as cases. Excluded
were women who. at baseline. had had irregular cycles in the
previous 6 months. were under the age of 60 with previous
hysterectomy. used oral contraceptives, post-menopausal oestrogen
or other hormones. had a history of oophorectomy or a previous
diagnosis ofcancer (except for non-melanoma skin cancer).
The control group comprised three control subjects per case
randomly selected from Guernsey [II study subjects alis-e and
without diagnosed cancer (apart from non-melanoma skin cancer)
at the end of follow-up for whom urine samples were located.
Control subjects were matched (baseline measures) to cases on age
(±2 years). date of baseline examrination (±1 year). baseline
menopausal status (premenopausal. 0-2 years or 3+ years post-
menopausal) and. if the case was premenopausal. then control
subjects were also matched on phase ofmenstrual cycle (follicular.
within 15 days of the start of the last menstrual cycle. or luteal.
more than 15 days). The same exclusion criteria were applied to
cases and control subjects. The control samples were retrieved and
assayed at the same time as the case samples (although not always
in the same batch) with the laboratorv blinded as to case-control
status. Matching, on date of baseline examination provides equal
follow-up time at risk of breast cancer for cases and control
subjects and also equalizes possible effects of duration of sample
storage.
Table 1 Characteristics of breast cancer cases and controls
Premenopausal at b ine Cases (n = 60) Controls (n = 184)
Mean (s.d.) age (years) 40.5 (4.3) 40.5 (4.2)
Mean (s.d.) age at menarche (years) 13.2 (1.5) 13.0 (1.4)
Mean (s.d.) weight (kg) 63.7 (9.9) 63.3 (10.4)
Mean (s.d.) height (cm) 162.2 (6.1) 160.7 (6.3)
Mean (s.d.) body mass index (kg i-2) 24.2 (3.1) 24.5 (4.1)
Mean (s.d.) age at first birth (parous) 24.7 (4.4) 24.4 (4.5)
Per cent parous 88 91
Per cent with first-degree family history 13 4
Per cent in first half of menstrual cycle 45 40
Median urinary 2-OHEl 18.4 17.5
Median urinary 16a-OHE1 9.9 8.5
Median 2:16a-OHE1 ratio 2.1 2.1
Post-menopausal at baseline Cases (n = 42) Controls (n = 139)
Mean (s.d.) age (years) 59.1 (6.6) 59.0 (6.2)
Mean age at menarche (years) 13.4 (1.9) 13.4 (1.5)
Mean (s.d.) weight (kg) 66.1 (8.8) 64.3 (9.9)
Mean (s.d.) height (cm) 158.2 (6.1) 159.1 (5.8)
Mean (s.d.) body mass index (kg n-2) 26.4 (3.1) 25.4 (3.6)
Mean (s.d.) age at first birth (parous) 26.9 (5.4) 26.1 (5.3)
Per cent parous 69 86
Per cent with first degree family history 12 10
Median years post-menopausal 7 7
Median urinary 2-OHEl 6.4 7.1
Median urinary 16a-OHE1 4.5 4.5
Median 2:16a-OHE1 ratio 1.6 1.7
Sample collection
Early moming spot urine samples collected at the 1977-85 survey
were stored at -20C without preservative (and not previously
thawed) for participants in the Guemsey III Survey.
Pilot study of stored urine samples
In order to determine whether the oestrogen metabolites remained
at measureable levels under long-term storage conditions. a pilot
study was completed in October 1995 using 30 randomly selected
Guernsey III spot urine samples: results showed measurable levels
similar to those found for more recent samples from healthy
middle-aged women. It is worth noting that in 1990 (after 5-13
years of storage) nearly 70 Guernsey III stored 24-h urine samples
were assayed for 2-hydroxyoestrone for a comparison of smokers
vs non-smokers (no significant difference found. unpublished) and
the values appeared to be acceptable.
Determination of oestrogen metabolite levels
Samples were shipped (overnight on dry ice) to the Strang Cancer
Research Laboratorv in New York City. Both 2-OHE1 and 16a-
OHE1 were measured using a competitise solid-phase enzyme
immunoassay (EIA) (Immuna Care Corporation. Bethlehem. PA.
USA) (Klug et al. 1994). The urinarv forms of these oestrogen
metabolites are found as glucuronide conjugates and required the
removal of the sugars before recognition by the monoclonal
antibodies. A mixture of 3-glucuronidase and arylsulphatase
(glusulase from H. pomatia. Sigma Chemical Co.) was used for
this purpose. The enzyme digest was then neutralized and 10-gl
aliquots are used in the assay. Assay incubation time is 3 h at room
temperature. After the addition of p-nitrophenol phosphate. the
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plates were incubated for 5 min. The assay was read kinetically, at
2-min intervals, using a Ceres 900 HDI plate reader (Bioteck
Instruments, Wmooski, VT, USA) and the data were reduced using
Kineticale EIA Application software (Biotek Instruments). Both
assays have been shown todemonstrate 100% recovery ofmetabo-
lites with serial dilution and 'spiking' of exogenous oestrogens
into urine samples. The within-assay coefficient ofvariation is 6%
and the between-assay coefficient of variation is 10%. The EIA
kits have been validated for each metabolite by comparison of
results with those obtained by gas chromatography-mass
spectrometry (Adlercreutz et al, 1975).
Analyse
Cases and control subjects were compared on the matching and
othervariables. The association ofmetabolite ratios with measured
factors was examined. (As history ofcigarette smoking was avail-
able for only about one-third ofthe subjects, it was not included in
the analyses.) Metabolite ratios for the case and control groups
stratified by menopausal status at baseline were examined and the
average percent difference between cases and control subjects was
computed from the case value of the ratio and the average value
for her matched control subjects. Fmally, to estimate breast cancer
risk according to tertile ofmetabolite ratio (based on control distri-
bution), odds ratios were calculated using conditional logistic
regression (i.e. retaining the matched sets), controlling forpossible
confounding variables such as parity.
In addition, baseline serum oestradiol concentrations had been
measured for 331 (83%) of the subjects as part of another study
(Thomas et al, 1997a; b), allowing examination ofthe relationship
between serum level and the urinary metabolite ratio.
RESULTS
Follow-up of the Guernsey HIl cohort for vital status and incident
breast cancer through May 1996 was over 94% complete. Of 146
women identified with incident breast cancer from the Guernsey
Ell study follow-up, samples for 111 were shipped for metabolite
measurement and 102 are included in the analyses. Samples for
two cases were never collected, ten were not found in the frozen
sample bank and the remaining 23 cases were not eligible for this
study as they reportedoophorectomy, use ofoestrogen orunclassi-
fiable menopausal status at baseline. Ofthe shipped samples, eight
cases were diagnosed within 6 months ofbaseline and were there-
fore considered prevalent cases, and the urine sample from one
case yielded undetectable 16a-OHE1. Of the total 333 control
samples (three per case) shipped for measurement, ten had unde-
tectable levels of 16a-OHEI and/or creatinine. In addition, 24
were matched to the eight (ineligible) prevalent cases and three
were matched to the case with no measured ratio, resulting in total
number of control subjects with measured metabolites and
matched to eligible cases of296 and a total of323 with measured
metabolites.
Ratios were plotted according to time from collection of urine
sample to assay date and no patterns were observed. suggesting
that ratio values were not related to duration of frozen storage
(regression coefficient = -0.02, 95% CI =-0.07, 0.03, P = 0.41).
Good comparability between cases and control on subjects
matching factors is shown by results in Table 1. Median time from
baseline survey to sample assay did not differ between cases and
control subjects for premenopausal (17 years) or post-menopausal
Table 2 Speaman correlaon between metaboite ratio, serum level of
oestracol and baseline charactristic of contris accordin to menopausal
status
P eOs_-miopausal
(n = 139) (n = 184)
Age (years) -0.06 0.10
Weight (kg) -0.10 -0.11
Height (cm) -0.00 -0.06
Body mass index (kg nv2) -0.10 -0.09
Age at menarche 0.04 -0.17
Age atfirst birth -0.00 -0.14
Parity (among parous) -0.13 -0.12
Oestabdol -0.06 (n = 125) -0.18 (n = 116)'
*P= 0.05.
Tbke 3 Propori of cases wiin teriles of ratios as determined by
dstbuto among controls stdets, by menopausal status
Rato 2 16a-OHE1 PreMI0gaSal Ptenoausal
cames (n =60) ces (n = 42)
Tertile cut-off points Tertle cut-off points
Tertile 1 35% 36%
Tertle 2 1.72 37% 1.39 38%
Terile 3 2.4428% 2.0926%
(16 years) subjects. Cases andcontrol subjects diddiffersomewhat
in the expected direction on factors known to be associated with
breast cancerrisk. Forexample, cases were less likely tohave chil-
dren, had an older age at first birth, and were more likely than
control subjects to have a family history ofbreast cancer in a first-
degree relative. Among the post-menopausal women, cases had a
higher body mass index in contrast to the premenopausal women.
who did not differ in weight at baseline from control subjects but
did tend to be taller.
Metabolite ratios were not significantly associated with any of
the measured breast cancer risk factors among either the pre- or
post-menopausal groups (measured by non-parametric correlation,
Spearman's rho) as shown in Table 2, apart from a correlation of
-0.17 for age at menarche among post-menopausal women, which
reached a boerline significance level (P = 0.06).
However, a negative relationship (rho = -0.18, P=0.05) was
observed between the 2:16a-OHEI rato and serum oestradiol
among the 116 post-menopausal control subjects with both
measures and among cases and control subjects combied (n = 153)
Tabile 4 Odds ratios forbreast cancer in relaon to bwesttertie of 2-16a-
OHEl
Pre_mepeusal Odds ratio 95% Cl P-vakue
Tertie 1 (low) 1.0
Tertile 2 0.99 0.48-2.08 0.99
Tertle 3 (high) 0.75 0.35-1.62 0.46
P t-nenopaua
Tertie 1 (ow) 1.0
Tertile 2 1.11 0.47-2.64 0.81
Tertie 3 (high) 0.71 029-1.75 0.46
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(rho = -0.23. P < 0.01). The association ofserum oestradiol with the
ratio was determined largely by its positive relationship with the
level of 16a-OHEI (creainine-adjusted) with a Spearman's rho =
0.25 (P= 0.01) - showing little relationship with 2-OHEl (rho =
0.11. P=0.26). As the serum and urine samples were not taken on
the same day. these relationships could not be reasonably assessed
among the premenopausal women.
The 2:16a-OHEl ratio differed by menopausal status with a
higher ratio among pre- as compared with post-menopausal
women (median values. 2.07 vs 1.65. P < 0.001 Kruskal-Wallis
test. P = 0.03. T-test).
For comparison of current results with those from previous
studies that have examined the per cent difference between urinary
oestrogen metabolites between cases and control subjects (within
matched sets), we found a 15% lower average 2:16a-OHEI ratio
among post-menopausal cases than control subjects (11% lower
20HEI and 4% higher 16a-OHEI) and no difference between
premenopausal cases and control subjects in the ratio or the
metabolites separately.
When the 2: 16a-OHEI ratios were divided into tertiles
according to the distribution of the control subjects, separately for
the pre- and post-menopausal subjects, the proportion of cases in
the highest tertile was smaller for both pre- and post-menopausal
groups (26% and 28%) than the proportion ofcases falling into the
lower two tertiles (35-38%) (Table 3).
The relative risk of incident breast cancer during follow-up (as
estimated by the odds ratio) is shown in Table 4 forpremenopausal
(60 cases and 184 matched control subjects) and post-menopausal
subjects at baseline (42 cases and 139 matchedcontrol subjects). A
urinary 2:16a-OHEl level in the highest tertile at baseline
compared with the lowest was associated with a reduced odds ratio
of 0.71-0.75 for incident breast cancer. Whereas both pre- and
post-menopausal women in the highest tertile of2:16a-OHE1 had
an odds ratio consistent with about a 30% lower risk as compared
with those in the lowest tertile. the results were statistically non-
significant. as shown by the 95% confidence intervals. which all
encompassed an OR of 1.0. Women with ratios in the middle
tertile showed no appreciable difference in risk from those in the
lowest tertile (reference group).
DISCUSSION
Oestrogen metabolism that markedly favours the 2-hydroxy-
oestrone over the 16a-hydroxyoestrone pathway was linked
prospectively to a reduced risk of breast cancer consistent with
previous case-control study results in post-menopausal women.
The present case series was not large enough to identify a statis-
tically significant reduction in risk ofabout 30% for women in the
top tertile of 2:16a-OHE1 ratio at baseline. This study. which
included a total of 102 incident breast cancer cases and 296
matched control subjects had fewer than one-halfofthe number of
case-control sets required to detect the reported odds ratio of0.7.
Given a minimum detectable significance level of0.05 and power
of 80%. over 250 case-control sets (1:3 matching ratio) would be
required (Breslow and Day. 1987). Thus. using the upper tertile as
the 'exposure category', the study lacked power to detect less than
a twofold difference in relative risk. Therefore, the results reported
here provide support, but not definitive evidence, for the hypoth-
esis that oestrogen metabolism plays a role in risk ofbreast cancer.
That any association between urinary oestrogen metabolites and
breast cancer risk was observed may be seen as remarkable given
that the urine was collected years before diagnosis of cancer and
assayed between 12 and 19 years after collection. Further, the
similarity in the per cent difference in ratios between post-
menopausal cases and control subjects to results of case-control
studies is stiking.
It should be noted that nearly all (77%) of the incident breast
cancers among subjects who were premenopausal at baseline
occurred after the age of45 years when the women were likely to
be peri- or post-menopausal at diagnosis. We examined whether
the risk estimates differed according to time from baseline to diag-
nosis ofbreast cancer, the estimated odds ratio associated with the
highest tertile ofthe ratio did not differ forcases diagnosed within
10 years of baseline (about half the cases) from the risk estimate
for those diagnosed 10 years or more after baseline. The fact that
time to diagnosis appears to have had no impact on the
ratio-breast cancer relationship (in spite of a long follow-up
period) suggests that: (1) the observed metabolite ratios at baseline
were not determined by pathogenesis and reflect individual differ-
ences in oestrogen metabolism, or (2) that breast cancer has an
extremely long incubation period and oestrogen metabolism may
be a consequence ofearly subclinical disease.
Reltionship of urinary ratios to serum concentrtons
ofoestrgens
Whether metabolism ofoestrogen may have a role in disease aeti-
ology separate from that of serum level of oestrogen is currently
under study (Ursin, 1997). Thomas et al (1997b) recently reported
baseline serum oestradiol to be strongly related to post-
menopausal breast cancer risk in this cohort, consistent with the
(negative) correlation observed between serum oestradiol and the
urinary 16a:20HEI ratio, although the correlation was not high
(= -0.18 in post-menopausal women). We found no change in the
estimate (odds ratio) of breast cancer risk associated with the
metabolite ratios when tertiles of serum oestrogen were also
included in the logistic regression model for post-menopausal
breast cancer cases and control subjects, suggesting independent
effects ofserum level and metabolite ratio. Results ofthe study by
Thomas et al (1997b) and the current study taken together show
that, for post-menopausal women, serum oestrogen level is more
strongly related to breast cancer nrsk than are urinary metabolite
ratios. Continued interested in the study of oestrogen metabolism
stems not only from its purported aetiological role in breast cancer
risk but from the possibility that, unlike serum level, the metabolic
pathways may be altered to influence risk. Whether women with
high serumoestradiol accompaniedby ahigh level of 16a-hydrox-
ylation are at particularly high risk of breast cancer is unknown:
the current study did not include sufficient women with both
measures to examine interaction.
Charactristics associated with an elevated
2:16a-OHE1 ratio
Health behaviours that may increase the 2:16-OHE1 ratio include: a
high level of physical conditioning (Snow et al. 1989). cigarette
smoking (Michnovicz et al. 1986) and dietary intake of indole-3
carbinole (13C). a phytochemical found in cruciferous vegetables
(Michnovicz et al. 1997). Moreover. feeding BC to tumour-prone
mice appears to lower their incidence of tumours (Bradlow et al.
1991). Anexperimental study toexamine low-fatdietamong female
volunteers found decreased urinary excretion of 16-hydroxylated
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metabolites (oestriol and 16ax-OHE ) and increased catechol oestro-
gens (2-OHE1 and 2-methoxyoestrone) with a low-fat as contrasted
with a high-fat diet (Longcope et al, 1987). although we have
reported no change in urinary metabolite ratios in a randomized trial
ofhealthy premenopausal women treated with a 25% total fat diet as
compared with acontrol group consuming a 36% fat diet (Pasagian-
Macauley et al. 1996).
We found modest (<-0.2) negative correlations between the
2:16-OHEl ratios and several previously established risk factors
for breast cancer:body mass index, weight (but not height) and
parity; among post-menopausal women only, we observed a nega-
tive correlation with age at firstbirth and also age at menarche. the
forner association but not the latter being consistent with a
reduced risk of breast cancer with a higher ratio. Also. we found
higher median ratios for pre- compared with post-menopausal
women (2.1 vs 1.7 among control subjects), suggesting a decline
in values with menopause.
If women who metabolize oestrogen predominately via the C2-
hydroxylation pathway have a reduced risk of breast cancer, then
risk may be altered favourably by promotion ofhealth behaviours
that increase oestrogen hydoxylation by this pathway. We were not
able to examine whether diet or exercise influenced the metabolite
ratio as this information was not available for this Guernsey study
cohort: nor did we have complete information on cigarette
smoking. although smoking does not appear to influence breast
cancer risk (Baron et al. 1996) and. therefore. is not likely to have
affected the observed risk estimates. C2-hydroxylation appears to
be more inducible than the 16a-OHEI and to be increased by
consumption of cruciferous vegetables and possibly by exercise.
This is in contrast to otherrisk factors forbreast cancer such as age
at first birth or serum oestrogen concentration, which are not
amenable to change via behavioural means. Thus, although long-
term health effects of alteration of oestrogen pathways are
unknown, advice to exercise more and eat more vegetables may
provide more than cardiovascular benefit for women: such
behavioral changes may also reduce their risk ofbreast cancer.
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